下一代肿瘤不可知靶点即将出现
Next-generation tumor-agnostic targets on the horizon.
肿瘤不可知药物开发将肿瘤学重新聚焦于共享的分子依赖性而非组织来源，从而能够针对跨肿瘤的罕见可操作驱动因素进行高效开发。
99.3分
★★★★★
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
T 细胞受体工程化 T 细胞治疗：快速演进的实体瘤治疗范式
英文原题：T-Cell Receptor Engineered T-Cell Therapy: A Rapidly Evolving Treatment Paradigm for Solid Tumors.
研究概要
外周血淋巴细胞可被工程化改造以表达识别HLA限制性肿瘤抗原的TCR，随后作为TCR-T细胞疗法进行全身给药。
中文摘要
外周血淋巴细胞可经工程化改造以表达识别人类白细胞抗原（HLA）限制性肿瘤抗原的T细胞受体（TCR），随后作为TCR-T细胞疗法进行全身给药。包括癌-睾丸抗原、病毒癌蛋白和新抗原在内的肿瘤特异性抗原谱不断扩大，使这种靶向方法在实体瘤患者中的潜在适用性日益广泛。尽管TCR-T细胞疗法已在转移性黑色素瘤和某些肉瘤患者的试验中显示出临床疗效，但目前它正逐渐成为一种针对错配修复功能正常上皮癌的有前景的研究性疗法。
展开英文摘要原文
Peripheral blood lymphocytes can be engineered to express T-cell receptors (TCRs) that recognize human leukocyte antigen (HLA)-restricted cancer antigens and subsequently administered systemically as TCR-T cell therapy. A growing repertoire of tumor-exclusive antigens including cancer germline antigens, viral oncoproteins, and neoantigens has led to a broadening potential applicability of this targeted approach in patients with solid tumors. While TCR-T cell therapy has already demonstrated clinical efficacy in trials of patients with metastatic melanoma and certain sarcomas, it is now emerging as a promising investigational therapy for mismatch repair proficient epithelial cancers.
论文信息
- 作者
- Leibou S、Dinerman AJ、Klemen ND
- 第一作者单位
- Surgery Branch, National Cancer Institute, National Institutes of Health, 10 Center Drive Building 10, Room 3-3750, Bethesda, MD 20892, USA.United States
- 通讯作者单位
- Surgery Branch, National Cancer Institute, National Institutes of Health, 10 Center Drive Building 10, Room 3-3750, Bethesda, MD 20892, USA. Electronic address: nicholas.klemen@gmail.com.United States
- 文献类型
- 综述
- 期刊
- Surgical oncology clinics of North America2026 Apr
- 原文标识
- PubMed 41903984 · DOI 10.1016/j.soc.2025.12.001